Shire agrees to license rare liver disease candidates to Mirum

This article was originally published here

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for

The post Shire agrees to license rare liver disease candidates to Mirum appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply